T. Van Leeuwen
- Cross-resistance risk of the novel complex II inhibitors cyenopyrafen and cyflumetofen in resistant strains of the two-spotted spider mite Tetranychus urticae
- Pest Management Science
- Volume | Issue number
- 70 | 3
- Pages (from-to)
- Document type
- Faculty of Science (FNWI)
- Institute for Biodiversity and Ecosystem Dynamics (IBED)
BACKGROUND: Cyflumetofen and cyenopyrafen are novel acaricides acting as complex II inhibitors. This new mode of action is extremely useful for devising efficient resistance management strategies for mite control. The authors determined the cross-resistance risk of both compounds, using a collection of well-characterised resistant strains of Tetranychus urticae, and also selected for cyflumetofen resistance in the laboratory.
RESULTS: Cross-resistance to cyflumetofen and cyenopyrafen was detected in field strains, with LC50 values exceeding the registered field dose. Synergism experiments suggested that P450 monooxygenases are involved in resistance, and that the activation mechanism of the two compounds most likely differs. Laboratory selection with cyflumetofen resulted in a highly resistant T. urticae strain that displayed negative cross-resistance to cyenopyrafen.
CONCLUSIONS: The cross-resistance risk of cyflumetofen and cyenopyrafen documented in this study needs to be integrated in resistance management strategies, especially in regions or crops with a history of frequent acaricide applications, in order to safeguard the efficacy of these compounds with a valuable new mode of action.
- go to publisher's site
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.